Title and author of burned, still-rolled scroll decoded after nearly 2,000 years
Researchers working to decipher the contents of a burned, still-rolled scroll have uncovered both the author and the title of the text nearly 2,000 years after it was buried in the Mount Vesuvius eruption.
The scroll — named PHerc. 172 — is one of hundreds from the ancient Roman town of Herculaneum, which was buried under volcanic debris when Mount Vesuvius erupted in 79 AD, according to the Vesuvius Challenge, an initiative focused on decoding the texts of the Herculaneum scrolls without needing to unroll them.
Preserved under mud and ash in a villa believed to have been once owned by the father-in-law of Julius Caesar, the scrolls were discovered by an Italian farmer in the 18th century.
Burned so badly they were carbonized, they are extremely fragile. Over the years, scholars have tried a range of methods to unroll them, including using weights, chemicals, gases and pulverization, though this often led to the scrolls being damaged or destroyed.
The Vesuvius Challenge was launched in 2023 to encourage researchers from around the world to try and decipher the scrolls by virtually unwrapping and decoding them.
Now, Marcel Roth and Micha Nowak, graduate students from Germany's University of Würzburg, have uncovered the title and author of PHerc. 172. Vesuvius Challenge researcher Sean Johnson made the same discovery around the same time, and both findings were independently reviewed by the competition's papyrological team, according to a Tuesday press release from Oxford University's Bodleian Libraries, where the scroll is housed.
The text deciphered identifies the scroll as 'On Vices' by the Greek philosopher Philodemus, according to the Vesuvius Challenge. It is a part of Philodemus' ethical treatise known in full as 'On Vices and Their Opposite Virtues and In Whom They Are and About What,' and could even be the first book in the series, though this is not yet clear.
Oxford University's Bodleian Libraries suggests that the book number could 'plausibly' be read as an alpha, which would indicate that the scroll is book one in the series, but it could also be other numbers, such as a delta, which would mean it is book four.
Scholars have generally thought that the first book of 'On Vices' was a text called 'On Flattery,' but the content of PHerc. 172 does not correspond with this.
Philodemus, according to the Bodleian Libraries, was an Epicurean philosopher whose teachings 'emphasise the pursuit of pleasure as central to a good life.' The majority of the scrolls found preserved in the Herculaneum villa were his works, Bodleian Libraries said.
Michael McOsker, a researcher in papyrology at University College London, who is also a member of the Vesuvius Challenge papyrology team, called the new discovery a 'very exciting development.'
'Other books from the On Vices and their Opposite Virtues are known from the papyri that were physically unrolled — best known are On Property Management (book 9, presumably the opposite virtue to greed) and On Arrogance (book 10, presumably the opposite vice to having a correct evaluation of yourself), but there are others too,' McOsker said.
'This will be a great opportunity to learn more about Philodemus' ethical views and to get a better view of the On Vices as a whole, especially if it turns out to be the first book,' McOsker said.
This find, the first time a scroll's title has been read, is the latest from the Vesuvius Challenge.
In October 2023, the first full word from one of the unopened ancient papyri was decoded with the help of computer technology and advanced artificial intelligence. The word was 'πορφυρας' or 'porphyras,' which is Greek for purple.
And in February, researchers investigating columns of text from PHerc. 172 identified the word 'διατροπή,' meaning 'disgust,' which appears twice within a few columns of text, the Bodleian Libraries said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
4 hours ago
- Medscape
Insulin Resistance Linked to Faster Cognitive Decline in AD
Insulin resistance, detected using a simple and readily available blood test, may flag cognitive decline in patients with early Alzheimer's disease (AD), preliminary results of a new study suggested. Using the triglyceride-glucose (TyG) index to measure insulin resistance, investigators found that cognitive decline was four times faster in individuals with mild cognitive impairment (MCI) due to AD who had the highest insulin resistance levels compared to those with lower levels. The findings underline the importance of risk stratification strategies and early interventions to change the trajectory of cognitive decline, lead author Bianca Gumina, MD, neurology resident, Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, told Medscape Medical News. 'The results suggest that in MCI-AD, the brain seems to be more vulnerable to metabolic stress. By identifying and addressing modifiable risk factors like metabolic health, we can use the tools we already have to potentially slow the disease course,' Gumina said. The results were presented on June 23 at the Congress of the European Academy of Neurology (EAN) 2025 in Helsinki, Finland. A 'Practical Tool' While insulin resistance has been linked to AD onset and pathology, its role in how rapidly the condition progresses has remained unclear. The single-center retrospective study included 315 patients without diabetes who had a neurodegenerative disorder (NDD) detected through cerebrospinal fluid (CSF). Of these, 210 had AD (mean age, 71.51 years; 79% men), and 115 had another NDD, mostly Lewy body dementia or frontotemporal dementia (mean age, 69.19; 60% men). Baseline measurements included neurologic evaluations, the Mini-Mental State Examination (MMSE) to test cognition, CSF biomarkers (Abeta42 or pTau181), APOE4 genotyping, and blood-brain barrier (BBB) integrity (CSF/serum albumin ratio). Follow-up assessments involved cognitive testing, typically every 6 months, with most patients followed for 3 years. Cognitive decline was defined as a loss of more than 2.5 points per year on the MMSE. Investigators measured insulin resistance with the TyG index, a metabolic marker calculated from fasting triglycerides and fasting glucose levels. The index, which Gumina called a 'practical tool,' can be obtained from standard blood tests. Researchers stratified patients into tertiles (low, medium, or high) according to TyG index levels. Exacerbating Neuroinflammation After adjusting for age, sex, baseline MMSE, disease duration, AD therapy, and BMI, the study found high TyG was significantly associated with faster cognitive decline over 3 years in a subgroup of 161 subjects with MCI (77% men) compared to those with lower TyG levels (hazard ratio, 4.08; 95% CI, 1.06-15.73). Insulin resistance may accelerate AD progression by impairing brain glucose uptake, said Gumina. This could exacerbate neuroinflammation and disrupt the BBB, 'all of which accelerate neurodegeneration,' she added. The study did link high TyG to elevated BBB permeability, but only in patients with AD. 'This supports the hypothesis that metabolic dysfunction may worsen neurodegeneration via mechanisms specifically related to AD,' said Gumina. Researchers observed an association between TyG and conversion from MCI to dementia, although this trend was not significant. Insulin resistance did not affect clinical progression in those with a neurodegenerative disease other than AD, which again likely reflects a disease-specific mechanism, said Gumina. 'AD may be the most sensitive to metabolic stress due to its underlying pathology,' she said. The study found no significant interaction between TyG and APOE4 genotype on the rate of cognitive decline. Speeding Disease Progression These new results show that insulin resistance 'influences the speed of disease progression, especially in early stages, which could be the most vulnerable in modifying the trajectory,' said Gumina. The findings could lead to more prompt identification of high-risk patients. 'By using the TyG index, we can stratify MCI patients by risk of fast progression, enabling personalized follow-up and interventions when the brain is still more responsive,' said Gumina. She recommends more widespread use of the TyG test, especially in patients with MCI or early AD. 'It's already available through routine and simple blood tests, found in every lab, so it could be used to flag patients for closer monitoring or early intervention.' Such interventions could include targeted enrollment in anti-amyloid or anti-tau clinical trials and timely introduction of lifestyle modifications and perhaps medications to improve insulin sensitivity. 'Lifestyle changes like regular exercise, a healthy diet, weight control, and managing blood pressure and cholesterol are all effective,' said Gumina. 'Some medications that modify insulin resistance are also under investigation.' The research team is investigating whether the TyG index correlates with neuroimaging biomarkers and integrating it with genetic and imaging data to improve prediction models. Important Puzzle Piece Commenting on the findings for Medscape Medical News , Sebastiaan Engelborghs, MD, PhD, professor and chair of Neurology, Vrije University Brussels, Brussels, Belgium, said the study 'adds an important piece to the Alzheimer's puzzle . ' The results highlighted how a routine metabolic marker such as the TyG index could help identify patients most likely to benefit from early, targeted interventions, said Engelborghs, who co-chaired the EAN panel on dementia and was not part of the research. And with precision neurology becoming ever more relevant, 'such noninvasive and low-cost tools could become critical in tailoring care and optimizing clinical trial design,' he added. Engelborghs agreed lifestyle interventions could affect insulin resistance and noted research shows that 45% of dementias can be prevented or delayed by modifying 14 risk factors. One such risk factor is obesity, and insulin resistance 'goes hand and hand' with obesity, he said. 'We expect that people who modify their lifestyle in order to lose weight and reduce insulin resistance will decline more slowly,' Engelborghs said.
Medscape
5 hours ago
- Medscape
Can a Face Mask Diagnose Kidney Disease?
A face mask with specialized sensors was able to detect chronic kidney disease (CKD) based on exhaled levels of ammonia and other metabolites, according to the results of an Italian study. Sensors for ammonia and other relevant molecules achieved a 93.3% true positive rate and 86.7% true negative rate in detecting kidney diseases, reported Corrado Di Natale, professor of electronic engineering at the University of Rome Tor Vergata, Rome, and coauthors in a paper in the American Chemical Society's ACS Sensors . The study included 50 patients who had been diagnosed with CKD, alongside 48 healthy control individuals. Control participants were drawn from patients' family members and hospital staff at the same clinic. The test used a breath sensor embedded in a standard face mask. The sensors consisted of coated silver electrodes with a conductive polymer commonly used in chemical sensors. The electrodes were placed between the layers of a disposable medical face mask, with wires attached to allow an electronic readout of exhaled gases. The sensor was designed to detect CKD-related metabolites, including ammonia, ethanol, propanol, and acetone. The project involved people in several departments, including nephrology and electric engineering, Di Natale said. The goal was to make the device easy for medical staff and patients to use, not wanting to add a new complicated process for CKD testing, Di Natale added. 'It was actually very simple, very simple to use,' he said. Expanding Breath Analysis Di Natale told Medscape Medical News that his team plans to continue working on tools for the diagnosis of metabolic disorders and lung cancer via breath analysis. Physicians long have known that CKD and other diseases such as diabetes can affect how breath smells. An emerging field, called volatolomics, or volatilomics, seeks to identify changes in the composition of chemical byproducts expelled normally through breath. Diagnostics based on breath samples would offer an attractive advantage in ease of collection, but there are many hurdles that researchers would need to clear to bring a product like a breath-based CKD test to market, Paul J. Jannetto, PhD, president-elect of the Association for Diagnostics & Laboratory Medicine, Washington, DC, told Medscape Medical News . While the research published in ACS Sensors suggests promise, additional validation studies in larger cohorts would be required, Jannetto said. 'These preliminary small-scale studies are just the first step,' explained Jannetto, who is also a professor of laboratory medicine and pathology and vice chair of practice laboratory medicine at the Mayo Clinic, Rochester, Minnesota. One of the biggest challenges in efforts to develop breath-based diagnostics is addressing the sheer number of volatile organic compounds (VOCs) carried out of the body through exhalation, Jannetto noted. More than 1400 VOCs have been linked to human breath. A single human breath contains hundreds of VOCs, representing various pathophysiological processes that alter a person's metabolic state, wrote Pritish Varadwaj of the Indian Institute of Information Technology Allahabad, Prayagraj, India, and coauthors in 2023 in Molecular Diagnosis & Therapy . 'Electronic Noses' There's been a long-standing interest in developing breath-based tests, or 'electronic noses,' for lung cancer, including a 2003 paper from Di Natale and coauthors in the journal Biosensors and Bioelectronics . Researchers in the UK and China have also published recent reports detailing attempts to develop an e-nose. Among the most developed projects in this field is an e-nose collection device currently in a clinical trial of about 119 patients. Gaetano Rocco, MD, of Memorial Sloan Kettering Cancer Center, New York City, the principal investigator for this study, said early results indicate the technology agreed with histopathologic results 86% of the time when assessing for lung cancer in very small nodules detected by a CT scan. Further testing continues on the ability of this e-nose device 'to modulate its response according to different phases of the patient's clinical history — ie, to detect the response after treatment of thoracic cancers, irrespective of the type of treatment (surgery, chemo and immunotherapy),' Rocco told Medscape Medical News via email. Successfully developing an e-nose would result in a technology to aid patients at a high risk for lung cancer, as it could 'guide the timing of the imaging, thereby avoiding multiple CT scans,' Rocco added. 'This would decrease costs and radiation exposure; in addition, the miniaturization of the technology will serve the purpose of allowing the patients to self-screen by breathing in the collection device in the comfort of their homes.' Di Natale received financial support from the European Union-NextGenerationEU (project ECS 0000024 Rome Technopole). Rocco and coauthors received support from National Institutes of Health/National Cancer Institute Cancer Center Support Grant P30 CA008748 and Memorial Sloan Kettering's Fiona and Stanley Druckenmiller Center for Lung Cancer Research. Rocco reported having a financial interest with Scanlan International, Merck, and Medtronic. Further author disclosures are available in the text of the paper.
Bloomberg
8 hours ago
- Bloomberg
How Extreme Heat Is Testing the Human Body's Limits
Extreme heat is becoming more frequent and intense due to climate change, testing the limits of the human body. Thousands of people across the world die each year from excessively high temperatures. A failure to mitigate global warming could result in more than 5.8 million extra heat-related deaths across European cities by the end of the century, according to a study published in Nature Medicine. That's equivalent to roughly twice the current population of Rome.
